We are thrilled to announce that Oleena, is now CE marked! This 12th regulatory clearance paves the way to the future commercialization of our oncology DTx in the Europe to support patients and their care teams in the management of cancer treatments.
👉https://t.co/v04eL3AE7Y
We are proud to announce our new collaboration with Eisai to co-develop innovative digital therapeutics to support patients with cancer based on Theraxium, our core DTx platform.
Learn more about this new collaboration here: https://t.co/cO1zYPxI3d
It has been a very busy month for Voluntis with the announcement of several pieces of good news!
Well done and thank you to everyone that contributed to these great achievements and made these new collaborations possible! 🎉
To read the latest news: https://t.co/2hCjZOjio0
👏🏻@voluntis successfully completed a capital increase of €5.9 Mln also subscribed by @DebiopharmNews https://t.co/lzlZ7HYP9h Debiopharm oversaw the #FH20 Lausanne Local hub and curated a session on #AI and virtual #clinicaltrials https://t.co/sFIXMLCMfW
Voluntis is committed to the fight against male cancers and diseases by participating in the #Movember Challenge to raise awareness. Let's make sure that our friends, brothers, husbands, sons and fathers are aware to get screened.
Voluntis extends its long-standing partnership with @Microsoft to meet worldwide demand on Digital Therapeutics. We're delighted to announce that we upgraded our secure cloud infrastructure with Azure!
To learn more, please read the press release: https://t.co/NH1PynlcCW
We’re delighted to announce our new strategic partnership with @Redox the leading interoperability platform for healthcare data exchange.
To learn more, read the press release :
https://t.co/eI7gz7iW7t
Our SVP Global Strategic Alliances, Damien McKeon, will be speaking tomorrow at the virtual event #DTx London during an interactive roundtable on the theme: “How to Commercialise Across Europe and is Pharma the key?”.
To watch the event, get registered at https://t.co/GnuAWIz68Y
We are delighted to start collaborate with @BioconBiologics India Limited, a fully integrated ‘pure play’ biosimilars company, to develop and distribute globally innovative digital therapeutics supporting people with diabetes on biologics therapy. #DTx
https://t.co/mMG9K2KUyj
Voluntis ensures continuity during COVID-19 crisis.
Our teams are working from home and remain 100% committed to maintaining excellent quality of service as we continue to create and operate innovative digital therapeutics and telemonitoring solutions.#staysafe#StayHome#COVID19
Digital transformation of healthcare growth drivers include AI and virtual trials to empower patient outcomes, funding from public markets, regulatory innovation, and corporate alliances
https://t.co/Ck3ZVgoEtc
#HLTH2019 attendees: Don't miss today's panel discussion at 12:30pm with Voluntis CEO, @PierreLeurent and other industry leaders as they explore Reimbursement Challenges and the Potential for Digital Overload with Emerging Digital Therapeutics.#digitaltherapeutics#digitalhealth
Our team is thrilled for the @aafp Annual Conference in Philadelphia this week! Visit us at Booth 412 to learn about @InsuliaT2D, our digital therapeutic supporting basal insulin self-titration for people with type 2 diabetes. #type2diabetes#familyphysicians#DigitalHealth